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Purpose: The aim of this work was to formulate sodium alginate nanospheres of amphotericin B by 
controlled gellification method and to evaluate the role of the nanospheres as a “passive carrier” in 
targeted antifungal therapy. 
Methods: Sodium alginate nanospheres of amphotericin B were prepared by controlled gellification 
method, and the particle size analysis was carried out by scanning electron microscopy. The carrier 
capacity of sodium alginate was evaluated in terms of drug to polymer ratio. In vitro release study was 
carried out on all drug loaded nanospheres by the dialysis method. Release kinetics of drug from 
different drug loaded nanospheres was also determined. The in vivo antifungal efficacy of nanospheres 
bound drug vis-à-vis the free drug was evaluated in candidiasis- induced mice models.  
Results: Preparation of nanospheres through controlled gellification method yielded particles with a size 
range of 419.6 ± 0.28 nm. Studies on drug to polymer ratio showed a linear relationship between 
concentration of drug and drug loading capacity. In vitro release kinetic study revealed that the release 
of drug from the nanospheres followed Fickian diffusion. In vivo studies showed that the nanosphere-
bound drug produced a higher antifungal efficacy than the free drug.  
Conclusion: The formulated sodium alginate nanospheres containing amphotericin B was found to 
have better antifungal activity when compared to the free drug and also yielded sustained in vitro 
release. 
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INTRODUCTION 
Infections due to fungi of the genera Candida 
and Aspergillus have become major nosocomial 
causes of morbidity and mortality in 
immunocompromised individuals. Their 
incidence has increased during the last three 
decades in parallel with the number of such 
patients and it is now a frequent complication1,2. 
More recently there has been a substantial 
increase in the frequency of candidaemia 
caused by species other than Candida albicans.3 
 
Systemic candidiasis is associated with high 
mortality rate and prolonged hospitalization.4 
The treatment options are extremely limited. 
Rapid treatment with amphotericin B or  
fluconazole is required to reduce the mortality 
observed in these patients.5 Amphotericin B is a 
very potent antifungal agent, but it has multiple  
severe toxic effects and about 36% rate of failure 
in the treatment of immunocompromised hosts.6 
Thus several lipid formulations (Ambisome®, 
Amphocil®, Abelcet®) have been developed and 
commercialized.7,8 Although they have been 
proven to reduce amphotericin B toxicity, their 
toxic effects and pharmacokinetic properties all 
differ and their use has been limited by high 
cost.  
 
One of the suitable methods to overcome these 
problems could be association with 
biodegradable polymeric carriers such as 
nanoparticles. Nanoparticles may become one of 
the successful carriers by overcoming problems 
caused by infections that are refractory to 
conventional treatment and also widening the 
therapeutic margin of antibiotics currently used 
in clinical practice.9,10,11,12 Hence, the objective of 
the work was to formulate sodium alginate 
nanospheres of amphotericin B by controlled 
gellification method, evaluate its 
physicochemical characteristics such as particle 
size, drug loading capacity, in vitro release 
characteristics, and also the in vivo efficacy in 
candidiasis-induced animal models. An 
important requisite in the realization of an 
injectable nanoparticle delivery system is the 
proper choice of the polymeric substrate. The 
polymeric bulk must fulfil many requirements as 
well as have suitable mechanical properties and 
biodegradability. Therefore, a suitable polymer 
such as sodium alginate was selected for the 




Amphotericin B was generously donated by 
Synbiotics Ltd, Baroda, India. Other materials 
used include sodium alginate, calcium chloride, 
poly-l-lysine, dialysis bag (Sigma Inc USA). SEM 
(JSM-6400 scanning electron microscope, 
Tokyo, Japan), research centrifuge R24 (Remi 
instruments), UV spectrophotometer (UV 160 A 




Preparation of sodium alginate nanospheres 
by controlled gellification method 
Sodium alginate nanospheres were prepared by 
the method reported by Rajaonarivony et.al,10. 
2ml of calcium chloride (18mM) was added to 
38ml of sodium alginate solution (0.1%w/v) to 
induce gellification. Then 16ml of poly-l-lysine 
(0.1%w/v) was added to form a polyelectrolyte 
complex. The nanospheres suspension obtained 
was stirred for 2 h and kept overnight for 
stabilization. The nanospheres were separated 
by ultra centrifugation at 20000 rpm for 45 
minutes and dried under vacuum to form a flaky 
mass, which on redispersion in sterile water for 
injection, produced discrete particles. 
 
Determination of particle size  
The nanospheres were spread over a glass slide 
and dried under vacuum at room temperature 
(25ºC). The sample was shadowed in a cathodic 
evaporator with a gold layer 20nm thick. The 
diameters of all the spheres in each field were 
calculated using a JSM-6400 scanning electron 
microscope (Tokyo, Japan).11 
 
Study on drug to polymer ratio 
To determine the drug: polymer ratio12, five 
batches of nanospheres containing various 
concentrations of drug were prepared. In each 
batch the concentration of drug was varied, while 
other processing variables were kept constant. 
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Amphotericin B equivalent to 10µg/ml was 
dissolved in 38ml of sodium alginate solution 
(0.1%). Then 2 ml of calcium chloride (18mM) 
and 16ml of poly-l-lysine (0.1%) was added, 
stirred for 2 h and kept overnight. The resulting 
nanospheres were separated at 20000 rpm by 
ultracentrifugation. The nanospheres were dried 
under vacuum. This batch coded ASA-I. 
Similarly ASA-II, ASA-III, ASA-IV and ASA-V 
were prepared, containing 20µg/ml, 30µg/ml, 
40µg/ml and 50µg/ml of amphotericin B, 
respectively. The batches were subjected to 
particle size analysis by SEM. 
 
Determinations of drug content 
An ultracentrifugation technique13 was used to 
separate the free drug from nanospheres and to 
estimate the drug loading of the nanospheres. 
The final colloidal suspensions were ultra 
centrifuged at 10000 rpm at 22 ± 2 ° C for 0.5 h. 
The supernatant was analyzed for drug content 
by measuring the absorbance at 345 nm using 
UV spectrophotometer. 
In vitro release studies 
The drug release assessment was carried out 
following the procedure reported earlier15, which 
employed a diffusion cell. A Sigma dialysis 
membrane was fixed to one end of a permeation 
cell. The nanospheres were placed in the cell 
donor compartment and the cell was immersed 
in a beaker containing 50ml of phosphate buffer 
(pH 7.4) which serve as a receptor compartment. 
The cell was immersed to a depth of 1cm below 
the surface of the receptor solvent. The medium 
in the receptor compartment was agitated using 
a magnetic stirrer and temperature of 37 ± 10C. 
5ml of the sample from the receptor 
compartment was taken at various intervals of 
time over a period of 24 h and each time 
replaced with fresh buffer. The samples 
withdrawn were estimated 
spectrophotometrically at 345nm. 
In vivo studies in candidiasis induced mice 
models 
The institutional animal ethics committee of JSS 
College of pharmacy approved the protocol 
study. The in vivo study was carried out in 
candidiasis induced mice models as reported 
earlier14. A total of 30 animals were taken, and 
divided into 3 groups. All 3 groups were induced 
with candidiasis by intravenous administration of 
0.1ml of 105 to 106 cells/ml of cell culture 
suspension. After 24 h of candidiasis induction, 
the Group I was treated with nanospheres bound 
amphotericin B, Group II with free amphotericin 
B. In each case, bound drug and free drugs were 
dispersed in sterile water for injections. The dose 
of the drug was 100mg/kg of animal weight and 
the volume of injection was 1ml/100g of mouse. 
The doses were given once a day for 7 
consecutive days. Group III (control) was treated 
with solvent only. The animals were observed for 
mortality for 16 consecutive days. The mice were 
sacrificed at the end of 16th day by cervical 
dislocation and dissected immediately. Organs 
like kidneys, lungs and liver were removed and 
homogenized in 5ml of sterile saline with Tween 
80. The number of colony forming units (CFU) in 
each homogenate was determined by plate 
counts on Sabourands dextrose agar media 
(SDA) containing 0.05mg/ml of chloramphenicol. 
 
RESULTS AND DISCUSSION 
Preparation of nanospheres by controlled 
gellification involves formation of calcium 
alginate complexes. The interaction between the 
calcium ions and the alginate polymer occurred 
at the level of the oligopolyglucuronic 
sequences. Furthermore, calcium ions induced a 
parallel packing of the oligopolyglucuronic 
sequences to give egg-box structures and the 
addition of poly-l-lysine allowed only 
strengthening of this system to obtain small and 
well defined particles. The obtained 
nanospheres were spherical and discrete with an 
average particle size of 419.6 ± 0.28 nm.  
 
Drug-loading capacity  
The drug carrier capacity of sodium alginate with 
respect to amphotericin B was determined 
assessing the drug: polymer ratio. As Table 1 
shows, the drug loading capacity was observed 
to have a direct linear relationship, with the drug 
loading capacity increasing as the concentration 
of drug increased. Thus, it can be said that the 
saturation capacity of the polymer with respect to 
the selected drug occurred at a relatively lower 
concentration and at a faster rate. 
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Release kinetic analysis 
The in vitro study of all the five batches showed 
an initial burst release within 30 min and 60% of 
the drug was released in a slow manner over 24 
h. In order to predict and correlate the release  
 
 
Table 1:  Amphotericin B - loading efficiency of sodium alginate nanospheres 
 
Formulation code Drug concentration 
(µg/ml) 
Drug loading  
(%) 
ASA I 10 10.7 ± 0.2 
ASA II 20 13.5 ± 0.6 
ASA III 30 17.2 ± 0.8 
ASA IV 40 22.6 ± 0.4 
 ASA V 50    27.3  ± 0.7 
 
 
Table 2:  In vitro release kinetics of amphotericin B- loaded nanospheres 
 
First order plot Peppa’s Formulation 
code 
































































Table 3: Percentage mortality and colony forming units of nanospheres bound amphotericin  
B and free amphotericin B in organs of RES. 
 
Number of colony forming units (CFU) Drug treatment Mortality (%) 
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Control 100 1.8x104                     7.5x103                    1.9x104   
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Fig 2:  In vitro release profiles of amphotericin B from different batches of drug loaded sodium 
alginate nanospheres.  (♦) ASA I-10µg/ml, (■) ASA II-20µg/ml,    (▲) ASA III-30µg/ml, (×) ASA IV-
40µg/ml and (●) ASA- V-50µg/ml. 
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behavior of the drug from the hydrophilic matrix it 
is necessary to fit it to a suitable model. Hence, 
the release data were fitted according to the well 
known exponential equation16, often used to 
describe the drug release behavior from 
polymeric system: 
mt/m∞=  ktn      ………………………… 1 
Where mt/m∞ is the fractional release of the 
drug, ’t’ is the release time, ‘k’ is a constant 
which indicates the properties of the 
macromolecular polymeric system and n is the 
release exponent indicative of the mechanism of 
release. The ‘n’ value used for analysis of the 
drug release mechanism from the amphotericin 
B nanospheres were determined from log 
(mt/m∞) vs log(t) plots. To calculate the release 
constant, k, the logarithm of the remaining 
amphotericin B in nanospheres plotted versus 
time. The release of drug from nanospheres 
followed first order kinetics over a 24 h period. 
Drug loading is another factor that influenced the 
drug release rate from the nanospheres. 
Generally, increasing the drug content in the 
nanospheres increased. The values of ‘k’, ‘n’ and 
‘r’ for five different batches are reported in Table 
2, and the ‘n’ value was within 0.5132 to 0.5583. 
The results of kinetic analysis reveal that the 
release of amphotericin B from sodium alginate 
nanospheres followed Fickian diffusion.  
 
In vivo studies 
An effective treatment of systemic candidiasis 
with amphotericin B requires comparatively 
higher concentrations of the antifungal drug in 
major target organs, such as the  like lung and 
liver, which act as reservoirs of microbes and 
may lead to reoccurrence of infection. As Table 
3 indicates, the nanosphere-bound drug is 
relatively more effective than the free drug 
against the candidiasis in terms of significant 
reduction in the colony forming units (CFU) in 
liver and lungs (p<0.05 by SNK test). The 
significant reduction in colony forming units 
(CFU) in the liver and lung could be to enhanced 
drug localization of nanosphere- bound drug as 
a result of macrophage uptake.  The results 
obtained in this study showed a marked 
reduction in the CFU in organs of liver and lungs 
when compared with the CFU for groups treated 
with the free drug. The reduction in CFU as well 
as the fall in % mortality may facilitate a 
reduction in the total dose required for therapy. 
This, in turn, means that dose-related systemic 
toxicities could also be reduced. 
 
CONCLUSION 
The formulated sodium alginate nanospheres of 
amphotericin B were found to be an effective 
and natural carrier in terms of discrete particle 
size, optimum drug loading capacity, satisfactory 
in vitro release characteristics, and in vivo 
antifungal activity for the passive delivery of 
amphotericin B. Furthermore, the nanosphere-
bound drug may enhance drug localization in the 
RES. A possible beneficial fall-out is a reduction 
in total dose as well as dose-related systemic 
side effects.   
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